OTCQX:MRVFF - Post by User
Comment by
consultant99on Mar 07, 2016 5:18pm
210 Views
Post# 24631952
RE:RE:RE:RE:RE:P2 fails its Primary endpoints
RE:RE:RE:RE:RE:P2 fails its Primary endpointsThere is just enough confusion to keep a lid on the share price until we get through the options pricing period. The liklihood of any deal for ex-US rights would seem to be a couple of months out after careful evaluation of the data by potential marketing partners.
Perhaps we'll see something within the next six weeks closing the book on Nuvo Research which will give us a glimpse of the Q1 sales in the US. Thereafter the Q1 results for Pharma - probably in mid-May. Of course Pharma management could just update an Investor presentation as before and give us a look.
I don't expect any real strength in the share price until US sales concerns are put to bed and we have a better handle on the level of profitablity of the company. There is just too much confusion right now (revenues and expenses) and then there is the rising Canadian dollar. The press release sure didn't cut it with the bull board did it?
Markets hate confusion and uncertainty - right now there is plenty to consider.